US-based LifeNet Health LifeSciences has introduced TruVivo, an all-human cell-based liver system that can support the development and discovery of crucial drugs and compounds.
Touted as the biggest co-culture advancement in over ten years, TruVivo is claimed to offer stable and dependable results in terms of well to well, experiment to experiment, and user to user.
Offering the ease and flexibility of a 2D model along with the data that usually accompany 3D models, this 2D+ system has been proven during the wide research and development undertaken over several years.
Pharmaceutical and agriscience companies have undertaken extensive validation testing on TruVivo, with their findings figured in several scientific poster presentations, with the most recent being at the 2023 Society of Toxicology annual meeting.
LifeNet Health LifeSciences general manager Louis Dias said: “TruVivo delivers a superior combination of human relevance, reliability, simplicity, and longevity.
“We believe this system will accelerate the movement toward New Approach Methodologies to replace traditional, animal-based studies, making it a valuable tool in the pharmaceutical, agriscience and food industries.”
In contrast to other models that depend on cells from animal sources, TruVivo consists of primary human hepatocytes, in addition to endothelial and stromal cells, all drawn from donated human tissues.
All the cells are pre-screened by LifeNet Health via a qualification process.
Under this unique platform, cells are brought together in an optimised ratio, creating a native tissue-sort of architecture that imitates very much a human liver microarchitecture. This also forms a stable phenotype, including the synthesis of important biomarkers, functional bile canalicular networks, and metabolic pathways of Phase I and II.
LifeNet Health LifeSciences chief scientist Ed LeCluyse said: “TruVivo is an ideal system for applications that require prolonged or repeated compound exposures, because of the higher hepatocyte content and the stable, long-term activity of drug-metabolizing enzymes with minimal feeder-cell background contribution.
“This makes TruVivo a great option to meet the growing demand for a system that can test low-turnover compounds quickly and easily.”
Requiring only basic cell culture knowledge and standard cell culture equipment, TruVivo is easier to use as against present liver models, as all components, including cryopreserved cells and required media, can be stored on-site, thereby enabling researchers to gain flexibility and control over their experimental workflows.
LifeNet Health president and CEO Rony Thomas said: “This technological breakthrough reflects LifeNet Health’s continued commitment to accelerating discovery in the field of life sciences.
“TruVivo will expedite drug development efforts, supporting lifesaving pharmaceuticals, treatments and cures – bringing a new platform to researchers around the world.”